Intellipharmaceutics International Inc.

IPCI.H

CA4581733090

Pharmaceuticals

Delayed Toronto S.E. Other stock markets 16:00:00 21/03/2024 GMT			5-day change	1st Jan Change
0.08 ^CAD	-.--%		-11.11%	+6.67%

01-03	IntelliPharmaCeutics International Receives Conditional Approval For TSXV Listing	MT
2023	Intellipharmaceutics International Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended August 31, 2023	CI

Intellipharmaceutics International Inc. Reports Earnings Results for the Full Year Ended November 30, 2020

March 01, 2021 at 05:03 pm

Intellipharmaceutics International Inc. announced earnings results for the full year ended November 30, 2020. For the full year, the company announced total revenue was USD 1.401 million compared to USD 3.480 million a year ago. Operating loss was USD 4.678 million compared to USD 7.834 million a year ago. Net loss was USD 3.390 million compared to USD 8.084 million a year ago.

Latest news about Intellipharmaceutics International Inc.

IntelliPharmaCeutics International Receives Conditional Approval For TSXV Listing	01-03	MT
Intellipharmaceutics International Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended August 31, 2023	16/10/23	CI
Intellipharmaceutics International Inc. Reports Earnings Results for the Second Quarter and Six Months Ended May 31, 2023	14/07/23	CI
IntelliPharmaCeutics International Fiscal Q2 Loss Narrows on Higher Revenue	14/07/23	MT
Intellipharmaceutics International Narrows Fiscal Q1 Loss, Revenue Rises	06/06/23	MT
Intellipharmaceutics International Inc. Brief: Recorded net loss for Q1 of US$355,738 or $0.01 per common shar	06/06/23	MT
Intellipharmaceutics International Inc. Auditor Raises 'Going Concern' Doubt	04/06/23	CI
Intellipharmaceutics International Inc. Reports Earnings Results for the First Quarter Ended February 28, 2023	04/06/23	CI
Intellipharmaceutics International Inc. Brief: Announcing Cease Trade Order	07/03/23	MT
North American Morning Briefing : More Fed -3-	03/03/23	DJ
Ontario Securities Commission Denies Intellipharmaceutics' Application for Management Cease Trade Order	08/02/23	MT
Intellipharmaceutics International Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended August 31, 2022	14/10/22	CI
Intellipharmaceutics International Fiscal Q3 Loss Widens	14/10/22	MT
North American Morning Briefing : All Eyes on Bank -2-	14/10/22	DJ
North American Morning Briefing : Stock Futures -2-	22/07/22	DJ
Intellipharmaceutics International Inc. Reports Earnings Results for the Second Quarter and Six Months Ended May 31, 2022	21/07/22	CI
North American Morning Briefing : Bank Earnings -2-	14/07/22	DJ
Intellipharmaceutics International Inc. Reports Earnings Results for the First Quarter Ended February 28, 2022	14/04/22	CI
IntelliPharmaCeutics International Fiscal Q1 Loss Narrows	14/04/22	MT
Earnings Flash (IPCIF) INTELLIPHARMACEUTICS INTERNATIONAL Reports Q1 Loss $-0.03	14/04/22	MT
North American Morning Briefing : Stock Futures -3-	28/02/22	DJ
Intellipharmaceutics International Inc. Auditor Raises 'Going Concern' Doubt	27/02/22	CI
Intellipharmaceutics International Inc. Reports Earnings Results for the Full Year Ended November 30, 2021	27/02/22	CI
Intellipharmaceutics International Inc. Announces Kenneth Keirstead, A Member of Board of Directors, Passed Away	13/01/22	CI
Intellipharmaceutics International Inc. Reports Earnings Results for the Third Quarter Ended August 31, 2021	15/10/21	CI

Chart Intellipharmaceutics International Inc.

Duration

Period

Chart Intellipharmaceutics International Inc.

More charts

Company Profile

Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to a range of existing and new pharmaceuticals. It has developed several drug delivery systems based on this technology platform, with a pipeline of products in various stages of development in therapeutic areas that include neurology, cardiovascular, gastrointestinal tract (GIT), diabetes and pain. Its product portfolio includes Oxycodone Hydrochloride ER, Regabatin, Dexmethylphenidate ER, Metformin ER, Venlafaxine ER, Pantoprazole ER, Quetiapine ER, Lamotrigine ER, Levetiracetam ER, Desvenlafaxine ER, Ranolazine ER, and Carvedilol ER. Its product portfolio includes both new products and controlled-release generic products. It also provides analytical services.

Sector

Pharmaceuticals

Calendar

16/07/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
INTELLIPHARMACEUTICS INTERNATIONAL INC.	+6.67%	1.94M
ELI LILLY AND COMPANY	+32.09%	694B
NOVO NORDISK A/S	+29.39%	593B
JOHNSON & JOHNSON	-1.34%	371B
MERCK & CO., INC.	+20.34%	331B
ABBVIE INC.	+7.39%	290B
ASTRAZENECA PLC	+14.25%	239B
ROCHE HOLDING AG	-3.03%	209B
NOVARTIS AG	+10.02%	209B
AMGEN INC.	+8.49%	169B